Empagliflozin: all 403 studies that test it
Page 3 of 5. Open to participants first (103), then studies with results posted, then the rest; newest registration first within each.
- Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.CompletedNCT07556094Not applicable
- Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 DiabetesCompletedNCT07541456Phase 4
- Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting ConditionsCompletedNCT07479108Not applicable
- Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast ConditionCompletedNCT07372118Phase 1
- Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgCompletedNCT07266766Phase 1
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated TabletsCompletedNCT07213895Phase 1
- Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEFCompletedNCT07169981Phase 2
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and ObesityCompletedNCT07120828Phase 4
- Empagliflozin on Patients With Preserved Heart FailureCompletedNCT07112274Not applicable
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)Active, not recruitingNCT07107945Phase 3
- A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and TogetherCompletedNCT07035457Phase 1
- A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With FoodCompletedNCT06962826Phase 1
- Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes MellitusCompletedNCT06952231Phase 3
- Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen TensionActive, not recruitingNCT06933355Phase 4
- Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsCompletedNCT06932159Phase 1
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseCompletedNCT06926660Phase 2
- Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard TreatmentCompletedNCT06915870Not applicable
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed TherapyTerminatedNCT06844669Phase 2
- Evaluation of Empagliflozin vs Standard Care in Veterans With PrediabetesCompletedNCT06828731Phase 1
- Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 InhibitorsCompletedNCT06825156Phase 4
- Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCTTerminatedNCT06818305Phase 2
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesCompletedNCT06762314Phase 2
- Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient DepartmentActive, not recruitingNCT06683053Phase 3
- Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes MellitusCompletedNCT06632561Phase 4
- Antithrombotic Activities of Sotagliflozin vs. EmpagliflozinCompletedNCT06618976Phase 4
- The Role of SGLT2i in Management of Moderate ASCompletedNCT06469645Phase 2/3
- Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)Active, not recruitingNCT06391450Phase 4
- Empagliflozin for No-reflow Phenomenon in PCI for STEMIActive, not recruitingNCT06342141Phase 2
- Empagliflozin Versus Vildagliptin in CAD Patients With T2DMCompletedNCT06313008Not applicable
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)WithdrawnNCT06280976Phase 4
- Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart DiseaseActive, not recruitingNCT06260059Phase 4
- Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of HyperglycemiaCompletedNCT06187285Not applicable
- Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting ConditionCompletedNCT06180109Phase 1
- EMPagliflozin After Aortic Valve ReplacementCompletedNCT06171802Phase 4
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese PatientCompletedNCT06145360Phase 4
- Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or MultimorbidityCompletedNCT06140108Phase 2/3
- Empagliflozin to Prevent Post-Operative Atrial FibrillationStatus unknownNCT06124937Phase 3
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialCompletedNCT06094920Phase 4
- Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesWithdrawnNCT06083675Phase 3
- Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsCompletedNCT06065280Not applicable
- Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic OutcomesStatus unknownNCT06021145Phase 4
- Empagliflozin in Treatment of Peripheral Diabetic NeuropathyCompletedNCT05977465Phase 1/2
- Efficacy and Safety of Empagliflozin in GSD-Ib PatientsWithdrawnNCT05960617Phase 2
- Mechanistic Insights to Weight Loss Maintenance Through SGLT2 InhibitorsWithdrawnNCT05885074Phase 2
- Novel Therapeutics and Endothelial Dysfunction in T1DM PatientsCompletedNCT05857085Phase 4
- This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.Status unknownNCT05823883Phase 1
- This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.CompletedNCT05823870Phase 1
- Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection FractionStatus unknownNCT05778084Phase 4
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)CompletedNCT05757791Phase 2
- Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue AssessmentCompletedNCT05694923Not applicable
- Empagliflozin in ESKD - A Feasibility StudyActive, not recruitingNCT05687058Phase 1/2
- Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.CompletedNCT05681273Phase 1
- Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKDCompletedNCT05614115Phase 1
- Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic SteatohepatitisStatus unknownNCT05605158Phase 3
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "Status unknownNCT05580510Phase 2/3
- Effects of Acute and Chronic Empagliflozin Heart FailureActive, not recruitingNCT05553938Phase 1
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin TherapyStatus unknownNCT05545800Phase 3
- Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for EpilepsyStatus unknownNCT05512130Early Phase 1
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT05510115Phase 2
- Empagliflozin in Pulmonary Arterial HypertensionCompletedNCT05493371Phase 2
- Empagliflozin as a Novel Therapy in Refractory AscitesCompletedNCT05430243Phase 2/3
- Use of Empagliflozin to Treat PrediabetesCompletedNCT05426525Phase 4
- Impact of SGLT2 on Glucosuria in HNF1A-MODYCompletedNCT05417646Not applicable
- Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease ProgressionCompletedNCT05373680Phase 2/3
- Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney DiseaseStatus unknownNCT05373004Phase 2/3
- The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury SurvivorsActive, not recruitingNCT05360615Phase 1
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes MellitusCompletedNCT05359432Phase 4
- Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?CompletedNCT05359341Not applicable
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesCompletedNCT05313529Not applicable
- Empagliflozin in Acute Heart FailureCompletedNCT05305495Phase 4
- Empagliflozin in Patients With GlomerulonephritisCompletedNCT05283057Phase 3
- Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on AnthracyclinesActive, not recruitingNCT05271162Phase 3
- Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed ConditionsCompletedNCT05229796Not applicable
- SGLT2 Inhibition: Uric Acid Excretion StudyCompletedNCT05210517Phase 4
- Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary SyndromeStatus unknownNCT05200793Phase 4
- Empagliflozin in Hypertrophic CardiomyopathyActive, not recruitingNCT05182658Phase 3
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With PrediabetesWithdrawnNCT05174507Phase 2
- Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B PatientsActive, not recruitingNCT05147090Phase 4
- Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection FractionCompletedNCT05139472Phase 4
- Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)CompletedNCT05132023Phase 1
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two DiabetesStatus unknownNCT05109949Phase 3
- The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart FailureCompletedNCT05084235Phase 2
- Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 DeficiencyCompletedNCT05078879Phase 1
- Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative ColitisWithdrawnNCT05058417Phase 2
- Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric BypassCompletedNCT05057819Phase 4
- The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart FailureCompletedNCT05042973Phase 2
- SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)Status unknownNCT05037695Phase 4
- Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of EmpagliflozinCompletedNCT05036421Phase 3
- EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial InfarctionActive, not recruitingNCT05020704Phase 3
- Empagliflozin in Diuretic Refractory AscitesCompletedNCT05013502Phase 1
- Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty LiverStatus unknownNCT04976283Phase 4
- Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney DiseaseStatus unknownNCT04961931Not applicable
- Safety and Efficacy of Empagliflozin in GSD1b Patients With NeutropeniaStatus unknownNCT04930627Phase 2
- Effects of Empagliflozin in Reducing Oxidative Stress After Kidney TransplantationCompletedNCT04918407Not applicable
- Empagliflozin in Adolescent DiabetesWithdrawnNCT04917692Phase 4
- Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone FormersCompletedNCT04911660Phase 2
- Follow-up of NAFLD Patients With MRI-PDFFCompletedNCT04910178Phase 4
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialStatus unknownNCT04796428Phase 4
- Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASHStatus unknownNCT04702490Phase 2